Shifting the diagnosis and treatment of atherosclerosis to children and young adults: A new paradigm for the 21st century

Journal of the American College of Cardiology

Volumn 40, Issue 12, 2002, Pages 2122-2124

  Tsimikas, Sotirios ^a   Witztum, Joseph L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ATHEROSCLEROSIS; AUTOSOMAL DOMINANT DISORDER; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FAMILIAL DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0037132642     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02599-8     Document Type: Editorial

References (23)

1. Palinski W, Napoli C. The fetal origins of atherosclerosis: Maternal hypercholesterolemia and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J 2002;16:1348-60.
2. Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea: Preliminary report. JAMA 1953;152:1090-3.
3. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA 1971;216:1185-7.
4. Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: The PDAY study. Pediatr Pathol Mol Med 2002;21:213-37.
5. Berenson GS, Wattigney WA, Tracy RE, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol 1992;70:851-8.
6. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: Evidence from intravascular ultrasound. Circulation 2001;103:2705-10.
7. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill, 1995;1981.
8. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8.
9. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
10. Davis ME, Harrison DG. Cracking down on caveolin: Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in modulating endothelial cell nitric oxide production. Circulation 2001;103: 2-4.
11. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82.
12. Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996;93:1647-50.
13. Penny WF, Ben Yehuda O, Kuroe K, et al. Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: Heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol 2001;37:766-74.
14. Palinski W, Tsimikas S. Immunomodulatory effects of statins: Mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002;13:1673-81.
15. de Jongh S, Lilien MR, Op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy induces complete normalization of endothelial dysfunction in Dutch children with familial hypercholesterolemia. J Am Coll Cardlol 2002:40;2117-21.
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
17. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
18. Stein EA, Illingworth DR, Kwiterovich PO Jr., et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: A randomized controlled trial. JAMA 1999;281: 137-44.
19. McCrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res 2002;51:715-21.
20. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: A randomized controlled trial. JAMA 2001;285:1711-8.
21. Brown BG, Zhao XQ Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
22. Tsimikas S, Shortal BP, Witztum JL, Palinski W. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol 2000;20:689-97.
23. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized LDL strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. In Press.